多烯磷脂酰胆碱联合复方丹参滴丸对非酒精性脂肪肝的临床研究

目的 研究多烯磷脂酰胆碱联合复方丹参滴丸对非酒精性脂肪肝患者的临床治疗效果。方法 选择2012年1月-2015年12月在西安医学院附属宝鸡医院进行诊治的非酒精性脂肪肝患者116例,随机分为观察组与对照组,每组58例。对照组采用复方丹参滴丸治疗,观察组采用多烯磷脂酰胆碱联合复方丹参滴丸治疗,均治疗3个月。比较两组的临床有效率;分别于治疗前后检测肝功能指标：天氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、γ-谷氨酰转肽酶（γ-GT）、总胆汁酸（TBIL）;血脂指标：总胆固醇（TC）、三酰甘油（TG）;肝纤维化指标：层粘连蛋白（LN）、透明质酸（HA）、Ⅲ型前胶原（PCⅢ）、IV型胶原（IV-C）;并进行上腹部CT平扫,计算肝/脾CT比值。结果 观察组的有效率为91.4%（53/58）,明显高于对照组的72.4%（42/58）（P<0.05）;与同组治疗前比较,治疗后两组的AST、ALT、γ-GT、TBIL、TC、TG水平均明显降低,肝/脾CT比值明显升高（P<0.05）,且观察组的改善程度明显优于对照组（P<0.05）;与治疗前比较,两组治疗后的LN、PCⅢ、IV-C和HA水平均明显降低（P<0.05）,且观察组的降低程度明显优于对照组（P<0.05）。结论 多烯磷脂酰胆碱联合复方丹参滴丸可以明显改善非酒精性脂肪肝患者的肝功能和肝纤维化,降低血脂。     

响应面法优化甘草制款冬花微波炮制工艺

目的 优化甘草制款冬花的微波炮制工艺。方法 以单因素实验作为基础,以紫外分光光度法(UV)和高效液相法(HPLC)测定甘草制款冬花中总生物碱、款冬酮、芦丁和异槲皮苷含量,结合醇浸出物含量的总评归一值为评价指标,对闷润时间、甘草用量、微波火力和炮制时间4个因素进行响应面实验研究,优化甘草制款冬花的微波炮制工艺。结果 甘草制款冬花的响应面法得出最佳工艺条件为闷润时间4.5 h、甘草用量15%,微波火力100%,炮制时间83 s,总生物碱、款冬酮、芦丁、异槲皮苷和醇浸出物含量分别为0.002 1%、0.283 6%、0.7%、1.44%和27.6%。结论 优选得到的甘草制款冬花炮制工艺合理、稳定、可行,可为甘草制款冬花的工业化生产提供理论依据。     

HPLC法测定阿德福韦酯片的含量和有关物质

目的建立高效液相色谱法测定阿德福韦酯片的含量和有关物质。方法采用Hypersil C18色谱柱,以乙腈-水(45∶55)(用磷酸调pH=4.0)为流动相,检测波长为261nm,流速为1.0mL·min-1。结果阿德福韦酯质量浓度在1.036⁶2.161μg·mL-1范围内线性关系良好(r=0.999 8),最低检测限为0.24ng,回收率为100.6%。结论该方法准确,灵敏,精密度高,专属性强,可用于阿德福韦酯片的含量测定和有关物质检查。     

洛氏硬度计（C标尺）测量结果的不确定度评定

目的：对本实验室洛氏硬度计（C标尺）测量结果的不确定度作以评定。方法：按照JJG112-2003《金属洛氏硬度计（A B C D E F G H K N T标尺）检定规程》,以C标尺为例,考虑洛氏硬度试验中标准硬度块、硬度计及试样等因素对洛氏硬度计（C标尺）测量结果的不确定度进行评定,即通过分析、计算洛氏硬度试验中产生不确定度的若干分量,计算出扩展不确定度。结果：洛氏硬度计测量结果的扩展不确定度对32.5 HRC标准硬度块为：y_1=y_1±U_（95）=33.11HRC±1.078HRC,k=2;对62.3 HRC标准硬度块为：y_2=y_2±U_（95）=63.31HRC±0.710HRC,k=2。结论：在洛氏硬度计检定过程中,测量结果的不确定度主要取决于洛氏硬度计的允许误差。评定结果令人满意,符合洛氏硬度（C标尺）的测量要求。     

装饰性彩色角膜接触镜性能检测的研究

参照角膜接触镜国家标准G B 11417.3-2012规定的质量要求及检验方法,对装饰性彩色角膜接触镜的部分性能进行检测分析,结合我单位近几年的检测情况进行探讨,提出一些思考和建议,以期对规范装饰性彩色角膜接触镜市场和提高其产品质量有所帮助。     

Retracted Article: Elevation of USP4 antagonizes oxygen glucose deprivation/reoxygenation-evoked microglia activation and neuroinflammation-mediated neurotoxicity via the TRAF6-NF-κB signaling

An ischemic stroke is a devastating neurological disease with the typical occurrence of brain ischemia/reperfusion (I/R) injury, and it has high mortality and disability globally. Microglia activation after a stroke results in the release of pro-inflammatory cytokines that can further aggravate brain damage. A recent study confirmed the potential role of ubiquitin-specific peptidase 4 (USP4) in the injury process. Nevertheless, the role and mechanism of USP4 during an ischemic stroke remain elusive. In this research, we simulated an I/R injury by oxygen glucose deprivation/reoxygenation (OGD/R) in vitro and confirmed the obvious down-regulation of USP4 in microglia under OGD/R conditions. Moreover, USP4 elevation antagonized the OGD/R-induced microglia proliferation and activation by suppressing the NO levels and the expression of the microglial marker IBA-1. Additionally, the overexpression of USP4 suppressed the release of microglia activation-induced pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α. Intriguingly, incubation with the conditioned medium from the microglia under OGD/R conditions induced neurotoxicity by inhibiting cell viability and increasing the LDH release, apoptosis, and caspase-3 activity, which were reversed following USP4 overexpression. Mechanism analysis corroborated that USP4 up-regulation repressed the OGD/R-induced activation of TRAF6-NF-κB signaling. Notably, restoring the TRAF6 signaling ameliorated the suppressive effects of USP4 elevation on microglia activation, inflammation, and the subsequent neuron injury. These findings suggest that USP4 may alleviate ischemic stroke by restraining microglia-mediated neuro-inflammation and neurotoxicity via the TRAF6-NF-κB pathway, due to which it is a promising therapeutic agent against strokes.

An ischemic stroke is a devastating neurological disease with the typical occurrence of brain ischemia/reperfusion (I/R) injury, and it has high mortality and disability globally.     

Induction of Matrix Metalloproteinase-3 (MMP-3) Expression in the Microglia by Lipopolysaccharide (LPS) via Upregulation of Glycoprotein Nonmetastatic Melanoma B (GPNMB) Expression

Substantial evidence suggests that inflammation is an important contributor to many neurodegenerative disorders. Activated microglial cells play an important role in releasing pro-inflammatory factors, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) for inducing inflammation. Recently, some reports have suggested that glycoprotein nonmetastatic melanoma B (GPNMB) is highly expressed in microglia after LPS treatment. However, the role of GPNMB in activated microglia is not clearly understood. In this study, we used RT-PCR and Western blotting to detect GPNMB and matrix metalloproteinase-3 (MMP-3) expressions in activated microglia. GPNMB small interfering RNA (siRNA) or MMP-3 inhibitor was applied on microglial BV2 cells, and ELISA was performed to measure the expressions of TNF-α and IL-1β in BV2 cells. Levels of iNOS and NO in BV2 cells were also determined. We found that the levels of GPNMB and MMP-3 were significantly increased in BV2 cells after LPS treatment. Moreover, we found that GPNMB significantly upregulated the expression of MMP-3 in BV2 cells, and high expression of MMP-3 was dependent on the level of GPNMB. Inhibition of GPNMB or MMP-3 expression by GPNMB siRNA or MMP-3 inhibitor dramatically suppressed the expressions of TNF-α, IL-1β, iNOS, and NO in activated microglia. All of these results suggest that GPNMB is involved in the inflammatory responses of microglia.     

食管鳞癌基因多态性表达与生存分析

目的:探讨食管鳞癌肿瘤组织中ERCC1、TYMS、TUBB3基因表达与预后生存的关系。方法:选择2012年9月至2016年5月我科收治的68例食管鳞癌患者,术后病理分期IIa-IIIa期;检测肿瘤组织ERCC1、TYMS、TUBB3 mRNA表达水平。术后患者分为个体化化疗组和标准化疗组,个体化组患者根据基因检测结果选择敏感药物化疗方案（CF/DCF/TC方案）进行化疗,标准组应用CF方案化疗,所有患者长期随访,统计化疗不良反应及生存数据。结果:肿瘤组织中ERCC1、TYMS、TUBB3阳性表达率分别为43%、47%、51%,无统计学差异（P＞0.05）。所有患者总一年生存率、两年生存率及三年生存率为分别为90.57%,72.45%和59.77%。生存曲线分析提示:0项基因阳性组预后最佳（P＜0.05）,而1项、2项和3项基因阳性组间无统计学差异（P＞0.05）。个体化化疗组的III/IV级化疗不良反应发生率明显低于标准化疗组（P＜0.05）。结论:食管鳞癌患者中ERCC1、TYMS、TUBB3表达具有特定的临床特征,其高表达患者预后欠佳。根据基因检测结果进行个体化化疗可以获得更好的疗效和耐受性,不良反应更轻。     

穴位注射配合自制药枕治疗颈椎生理弧度异常症的临床疗效观察

目的：探讨颈椎生理弧度异常症的病因和发病机制,观察穴位注射配合自制药枕治疗颈椎生理弧度异常症的临床疗效。方法：选取我院门诊收治的120例患者为研究对象,给予双侧风池穴局部注射配合自制药枕治疗3个疗程,随访6个月。结果：120例患者治愈93例,显效18例,有效4例,无效5例,总有效率为95.8%。结论：本法临床疗效好,简便、易操作、患者易于配合,值得推广。     

基于整合药理学的当归抗动脉粥样硬化的作用机制研究

目的 基于整合药理学,研究当归抗动脉粥样硬化(Atherosderosis,AS)的作用机制.方法 借助中药整合药理学平台(TCMIP V2.0),预测分析当归抗动脉粥样硬化的机制及其药效物质基础.结果 当归抗动脉粥样硬化的17种有效成分,直接或间接作用于PPARG(过氧化酶体增殖物激活受体)、APOE(载脂蛋白E)、...